Ind-Swift's Q1 FY25 financials show mixed results, with significant growth in PAT but decline in PBT and Net Sales

Ind-Swift, a microcap pharmaceutical company, recently announced its financial results for the quarter ending June 2024. The company’s stock has been given a ‘Sell’ call by MarketsMOJO.

According to the financials, Ind-Swift’s performance has remained flat in the quarter, with a score of 5 out of 11, a decrease from the previous quarter. However, there are some positive aspects to the company’s financials.

The Profit After Tax (PAT) for the quarter has shown a significant growth of 694.4% compared to the average PAT of the previous four quarters. This is a positive trend for the company in the near term.

On the other hand, the Profit Before Tax less Other Income (PBT) has fallen by -12.6% compared to the average PBT of the previous four quarters. The Net Sales for the quarter have also decreased by -9.3% compared to the average Net Sales of the previous four quarters. This shows a negative trend in the near term for the company.

The Operating Profit (PBDIT) for the quarter is the lowest in the last five quarters, indicating a negative trend in the near term. The Operating Profit Margin is also at its lowest in the last five quarters, showing a decline in the company’s efficiency.

Moreover, the Non Operating Income for the quarter is 141.40% of the Profit Before Tax (PBT), which suggests that the company’s income from non-business activities is high. This may not be a sustainable business model for the company.

Overall, Ind-Swift’s financial performance for the quarter ending June 2024 has been mixed, with some positive and negative aspects. Investors should carefully consider these factors before making any investment decisions.